Biotechnology companies are currently developing exosome-based vaccines against COVID-19 by displaying the SARS-CoV-2 S protein on the exosome surface or delivery of mRNA corresponding to viral proteins through exosomes. The gene discussed is PROS1; the disease is COVID-19.